Torrent Pharmaceuticals has delivered a robust financial performance in Q3FY26, with the company announcing its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. The pharmaceutical major demonstrated strong growth momentum across all key markets, reinforcing its position in both domestic and international segments.

Board Approves Interim Dividend and Financial Results

The Board of Directors approved the financial results and declared an interim dividend of ₹29 per equity share at their meeting held on February 13, 2026. The dividend, representing 580% on the face value of ₹5 per share, is expected to be paid on or around March 6, 2026. The board meeting commenced at 02:00 pm and concluded at 04:30 pm.

Strong Quarterly Performance Across Markets

The company's Q3FY26 results showcase impressive growth across all geographical segments. Total consolidated revenue reached ₹3,303 crores, marking an 18% year-on-year increase from ₹2,809 crores in Q3FY25.

Profitability Metrics Show Strong Growth

The company achieved significant improvement in profitability metrics during Q3FY26. Net profit after tax reached ₹635 crores, representing a 26% year-on-year growth. Operating EBITDA stood at ₹1,088 crores, up 19% from the previous year, maintaining a healthy margin of 33%.

Nine-Month Performance Sustains Growth Momentum

For the nine-month period ended December 31, 2025, Torrent Pharmaceuticals maintained consistent growth across all segments. Total revenue for the period reached ₹9,783 crores, representing a 14% increase from ₹8,557 crores in the corresponding period of the previous year.

JB Pharma Acquisition Progress

The company has made significant progress in its acquisition of JB Chemicals & Pharmaceuticals Limited. Torrent Pharmaceuticals has acquired a controlling stake representing 46.39% of JB Pharma's equity share capital and obtained control with effect from January 21, 2026. The company is in the process of obtaining requisite approvals from SEBI for the proposed scheme of merger. Upon merger, Torrent will issue 51 fully paid-up equity shares for every 100 shares held in JB Pharma.

Source:

Torrent Pharmaceuticals has successfully completed its strategic acquisition of equity shares in J.B. Chemicals & Pharmaceuticals Limited, marking a significant milestone in the pharmaceutical sector consolidation. The company announced on February 3, 2026, that it has acquired the final tranche of shares under its comprehensive acquisition agreements.

Final Share Acquisition Details

The latest acquisition involved 92,490 equity shares of JB Chemicals, purchased from an employee of the target company. This transaction was executed in accordance with the share purchase agreement dated July 3, 2025, which was specifically designed for acquiring shares from JB Chemicals employees.

Completion of Acquisition Program

Torrent Pharmaceuticals has confirmed that all equity shares targeted under its dual acquisition strategy have been successfully acquired. The acquisition program comprised two main agreements: the primary Share Purchase Agreement dated June 29, 2025, executed between Torrent Pharmaceuticals, Tau Investment Holdings Pte Limited, and JB Chemicals, and the supplementary employee share purchase agreement dated July 3, 2025.

Current Shareholding Position

Following the completion of this acquisition, Torrent Pharmaceuticals' total shareholding in JB Chemicals has reached a substantial position in the pharmaceutical company.

Regulatory Compliance and Documentation

The acquisition has been conducted in full compliance with SEBI regulations, specifically under Regulation 30 and Regulation 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Torrent Pharmaceuticals has maintained transparency throughout the acquisition process, with multiple intimations to stock exchanges dating back to June 29, 2025.

The completion of this acquisition represents a strategic expansion for Torrent Pharmaceuticals in the pharmaceutical sector, establishing a significant stake in JB Chemicals & Pharmaceuticals Limited. The systematic approach to the acquisition, involving both institutional and employee shareholdings, demonstrates the company's comprehensive strategy for building substantial positions in target companies.